We determined reactivity of human blood to a vaccine based on the recombinant N-terminus of candidal Als3p (rAls3p-N) in preparation for future clinical trials. Healthy donor plasma had high immunoglobulin G titers (median, 1:51,200) and lower immunoglobulin A (median, 1:3,200) and immunoglobulin E (median, 1:128) titers to rAls3p-N by enzyme-linked immunosorbent assay. rAls3p-N stimulated interferon γ (IFN-γ) and interleukin (IL)–17, but not IL-4, from donor lymphocytes by enzyme-linked immunosorbent spot assay and IL-12 p70, IFN-γ, IL-17, and IL-10 by cytometric bead array. Donors reacted to diverse immunodominant epitopes. Thus, facile humoral and cellular assays can monitor immune responses to the rAls3p-N vaccine in planned clinical trials.

We are developing a vaccine, based on the recombinant N-terminus of the Als3p surface adhesin from Candida albicans (rAls3p-N), which protects mice against otherwise-lethal disseminated candidiasis [1] and against disseminated Staphylococcus aureus seminated candidiasis [1] and against disseminated Staphylococcus aureus seminated candidiasis [1]. We also identified antibody titer cut-off values in vaccinated and control mice that correlated with survival versus mortality after infection [1, 4]. Hence, production of IFN-γ and IL-17 in response to vaccination, as well as anti-rAls3p-N antibody titers, are potential candidate assays for monitoring vaccine efficacy in future clinical trials.

As the rAls3p-N vaccine undergoes proper manufacturing development for a planned phase I clinical trial, it is necessary to establish relevant immunological assays to track vaccine immunogenicity. Such assays would become the basis for establishment of a surrogate marker of protection in future clinical testing in patients who are at risk for infection [5]. Because humans are colonized with Candida species (from which the rAls3p-N vaccine protein is derived), we hypothesized that healthy humans would have pre-existing immunity to the rAls3p-N protein. We developed humoral and cell-mediated immune assays to determine the magnitude and variability of immunity to rAls3p-N in healthy humans and sought to define the rAls3p-N epitope(s) responsible for these immune responses.

Materials and methods. Blood was drawn from healthy volunteers into Vacutainer CPT tubes (Becton Dickinson) for 1-step separation of plasma from peripheral blood mononuclear cells (PBMCs), in accordance with the manufacturer’s instructions. The human subjects component of the study was approved by the local institutional review board, and informed consent was obtained from all donors.

We developed human enzyme-linked immunosorbent assays (ELISAs) to detect immunoglobulin (Ig) G1, IgG2, IgG3, IgG4, total IgG, and IgA and IgE anti-rAls3p-N antibodies based on our previously described murine ELISAs [1]. In brief, rAls3p-N (amino acids 17 to 432 of Als1p) was produced in Saccharomyces cerevisiae and purified by Ni-NTA matrix affinity purification. Ninety-six-well plates were coated with rAls3p-N, blocked, and exposed to serial dilutions of human plasma. Negative control wells receive no primary antibody (ie, no plasma). Goat anti-human secondary antibody conjugated with horseradish peroxidase was added, followed by washing and incubation with O-phenylenediamine to generate a colorometric reaction. The reaction was terminated after 20 min with sulfuric acid. The ELISA titer was taken as the reciprocal of the last serum dilution with a positive optical density (OD) reading (ie, >OD of negative control samples + [standard deviation × 2]). PBMCs were plated at 2 × 10^5 cells per well in 100 μL of complete media on IFN-γ, IL-17, or IL-4 human enzyme-linked
immunosorbent spot (ELISpot) kits (eBiosciences). Cells were stimulated with rAls3p-N (12.5 μg/mL) plus anti-CD28 antibody (BD Pharmingen), heat-killed (60°C for 1 h) C. albicans germings (pre-germinated for 1 h at 37°C in Roswell Park Memorial Institute 1640 medium prior to killing) at a 2:1 ratio of organisms to PBMCs, media plus anti-CD28 antibody, or media alone. CD28 antibody was added to provide a second signal for T cell activation in the absence of professional antigen presenting cells in PBMCs. In some experiments, PBMCs were exposed to 20-mer peptides overlapping by 10 amino acids, spanning the length of the rAls3p-N protein (1 peptide per well at 50 μg/mL; peptides from Sigma). After 48 h of incubation, the plates were processed per the manufacturer’s instructions and read using a Biosys Bioreader 5000. Spot frequency in stimulated wells was corrected by subtracting background signal from wells with cells plus media alone and was normalized per 10^5 cells.

Production of IFN-γ, IL-4, IL-8, IL-10, IL-12 p70, and IL-17 were measured from ELISpot supernatants by Cytometric Bead Array Flex Sets (Becton Dickinson) and flow cytometry per the manufacturer’s recommendation. These cytokines were chosen because they reflect type 1 (IFN-γ and IL-12 p70), type 2 (IL-4, IL-10), and Th17 (IL-17, which induces IL-8 expression by other cells) responses.

The nonparametric Mann Whitney U test was used for unpaired comparisons, and the Wilcoxon signed rank test was used for paired comparisons. Correlations were determined by the Spearman rank test. P < .05 was considered to be statistically significant.

**Results.** To determine whether healthy humans have baseline anti-rAls3p-N antibody titers, plasma samples from 13 healthy donors were screened for total IgG and IgG1, IgG2, IgG3, and IgG4 subtype titers. We found that all donors had high anti-rAls3p-N IgG serum titers (median value [interquartile range], 51,200 [102,400–25,600]) (Figure 1A). All donors also had detectable Ig subtype titers against rAls3p-N. Titers were higher for both IgG1 and IgG3 subtypes than they were for IgG2 and IgG4 subtypes (P < .001 for IgG1 or IgG3 titers vs. both IgG2 and IgG4 titers).

IgA and IgE titers were also detectable in all donors, although they were lower than IgG titers (Figure 1A). Median (interquartile range) titers were 3200 (1600–12,800) and 128 (32–128) for IgA and IgE, respectively. IgA titers correlated with IgG titers in individual donors (r = 0.7; P < .001); IgE titers did not correlate with IgG titers (r = 0.4; P = .1).

IFN-γ and IL-17 have been shown to be critical to vaccine efficacy in preclinical studies; in contrast, IL-4 was dispensable for protection [1, 3]. To determine the strength of cell-mediated immunity to the vaccine protein, we evaluated IFN-γ, IL-17, and IL-4 production by PBMCs in response to rAls3p-N, as well as to pregerminated, heat-killed C. albicans (which expresses Als3p on its cell surface [6]). Thirteen of 14 donors demonstrated an IFN-γ response to the vaccine protein; all donors demonstrated an IFN-γ response to heat-killed C. albicans (Figure 1B). Overall IFN-γ production was significantly greater in response to the vaccine protein and to C. albicans than it was to media alone (P < .01 for both comparisons). IFN-γ production was also greater in response to C. albicans than it was to rAls3p-N (P = .001). PBMCs from most donors did not produce detectable levels of IL-4 (data not shown).

Eleven of fourteen donors demonstrated an IL-17 response to the vaccine protein; 12 donors demonstrated an IL-17 response to C. albicans (Figure 1B). IL-17 production was significantly greater in response to the vaccine protein and C. albicans than it was to media alone (P < .05 for both comparisons). IL-17 production in response to C. albicans and vaccine protein were similar. In paired PBMC samples, IL-17 production in response to both C. albicans and vaccine protein was less than IFN-γ production (P < .01 for both comparisons).

We also sought to determine whether there was a relationship between the strength of the humoral and the PBMC-mediated response to the vaccine protein in individual donors. In individual donors, serum anti-rAls3p-N titers did not correlate with PBMC production of either IFN-γ or IL-17 in response to rAls3p-N in ELISpot assays.

To determine the general profile of cytokines produced in PBMCs in the ELISpot assays, supernatants from the ELISpot wells were harvested prior to processing the plates. Cytokine levels in the supernatants were measured by Cytometric Bead Array Flex Sets. rAls3p-N induced expression of IL-12 p70 and IFN-γ, indicative of a type 1 immune response, as well as IL-17 (Figure 1C). rAls3p-N also induced expression of IL-10, but it did not induce expression of IL-4 or of IL-8.

Because the rAls3p-N–induced IFN-γ response was stronger than the IL-17 response in PBMCs from healthy donors, we used the IFN-γ ELISpot assay to identify immunodominant epitopes from rAls3p-N. ELISpot plates were coated with 20-mer peptides overlapping by 10 amino acids each, spanning the length of the rAls3p-N molecule (1 peptide per well). After 48 h incubation with PBMCs from individual donors, the number of spots in each well was quantified. Peptides inducing responses at the 95th percentile of magnitude (ie, ≥2 standard deviations above the mean response of all peptides) were considered to be immunodominant (Figure 2). The predominant IFN-γ inducing epitopes for individual donors spanned the entire length of the protein. Epitopes to which >1 donor was reactive were identified at multiple peptide positions. However, the highest number of reactive donors for any individual immunodominant peptide was only 4 (peptide 5 and 29). Furthermore, individual donors reacted to widely separated peptides.
Figure 1. Healthy human donors have preexisting immunity to the rAls3p-N vaccine protein. 

**A.** Serum samples from 13 donors were tested in immunoglobulin (Ig) G, IgG1, IgG2, IgG3, and IgG4 enzyme-linked immunosorbent assays to quantify rAls3p-N titers. Bars denote median titers.

**B.** Peripheral blood mononuclear cells (PBMCs) from healthy human donors produce interferon (IFN)-γ and interleukin (IL)-17 in response to the rAls3p-N protein and to pre-germinated, heat-killed Candida albicans. Results from 14 donors are shown in both graphs. Spots from each well were normalized per 10⁵ PBMCs. Bars denote median values. *versus media; **versus both rAls3p-N and media.

**C.** Supernatants from 6 donor PBMCs were assayed for cytokines by Cytometric Bead Array. Bars denote median values. *P < .05 versus media.
as well. However, the IL-17 response to whole healthy donors recognize other antigens aside from rAls3p-N, the response to rAls3p-N alone, suggesting that Th1 cells in found high IgG antibody titers and cellular production of both to a vaccine protein based on the Als3p adhesin. Indeed, we hypothesized that most humans would have preexisting immunity to a vaccine protein based on the Als3p adhesin. We found high IgG antibody titers and cellular production of both IFN-γ and IL-17 in response to rAls3p-N in healthy donors, confirming that humans have preexisting memory lymphocytes specific for the protein. The magnitude of cytokine responses detected were similar to those found to be produced by immune lymphocytes from vaccinated mice that were protected against infection [3, 7].

The IFN-γ response to whole C. albicans was greater than the response to rAls3p-N alone, suggesting that Th1 cells in healthy donors recognize other antigens from rAls3p-N, as well. However, the IL-17 response to whole C. albicans was similar to the response to the rAls3p-N protein, suggesting that Als3p may be a predominant antigen recognized by Th17 cells in healthy donors. The identification of numerous immunodominant epitopes in the rAls3p-N protein, which span the entire sequence of the protein both between and within individual donors, indicates that fragments of the vaccine protein are less likely to be broadly reactive to patient populations than is the whole vaccine protein.

In contrast to mice, which are neither colonized with nor pre-immune to Candida species and mount a naive T cell response to the first dose of the rAls3p-N protein [1], our data indicate that humans should mount a memory response to the first dose of vaccine in future clinical trials. We have shown that the rAls3p-N vaccine induces protection against disseminated candidiasis in mice as soon as 1 week after a single dose of vaccine [1]. Therefore, acutely at-risk humans are likely to derive an even more rapid survival advantage after vaccination. Because the mean (± standard deviation) time to onset of disseminated candidiasis is 22 ± 1 days of hospitalization [8], it should be feasible to vaccinate acutely at-risk patients to prophylaxis them from infection, based on early recognition of well established risk factors [9].

Although Candida colonization clearly leads to skin test reactivity in humans, the preexisting immunity to the organism is not protective, because colonization is a risk factor for disseminated candidiasis, not a protective factor [9]. The purpose of vaccinating at-risk hospitalized patients is to rapidly boost immunity to the organism during the critical acute-risk time period. Specific evidence in support of the ability of vaccination to enormously decrease disease in populations already colonized with and pre-immune to the targeted pathogen derives from the experience with Hemophilus influenzae and Streptococcus pneumoniae. The conjugated H. influenzae b vaccine has decreased invasive disease due to H. influenza by >95% in the United States [10]. Similarly, pneumococcal vaccines have significantly reduced the incidence of invasive infection [11]. This vaccine efficacy has occurred despite the fact that, akin to Candida species, both children and adults had significant oropharyngeal colonization rates (up to 60% in some studies) of H. influenza and S. pneumoniae in the prevaccine era [12, 13], but vaccination successfully increased antibody titers, increased the rate of eradication of colonization, and decreased subsequent invasive disease [14, 15]. Conversely, it is also possible that pre-existing immunity to Candida is nonprotective because the strength of preexisting immunity acutely decreases in highly at-risk patients. Thus, it is conceivable that boosting of the preexisting immune response may be blunted by acute immunocompromising conditions in at-risk patients. Future studies that determine the qualitative and quantitative immune responses to Candida species in acutely at-risk patients, as opposed to healthy donors, will be critical to determine whether preexisting immune deficiency can be boosted or circumvented by vaccination in future clinical trials.

In summary, we have confirmed that healthy humans have lymphocytes that have been previously primed to generate both a humoral and cell-mediated immune response specific to the rAls3p-N vaccine protein. Hence, vaccination will likely induce a memory response in acutely at-risk patients, rapidly boosting their immunity during the critical at-risk period. These data support the continued development of the rAls3p-N vaccine.
References


